Rett syndrome genetic registry for MECP2 changes
Part of Brain & nervous system, Genetic & congenital, Mental health clinical trials.
This trial is a registry that collects health and genetic information from people with Rett syndrome. It may help researchers better understand how MECP2 loss-of-function changes lead to symptoms and how to support patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed genetic change in MECP2 that causes loss of function (not just a harmless variant)
- You may be male or female, as long as the MECP2 change is the loss-of-function type
- You should have a diagnosis or genetic result showing the MECP2 loss-of-function alteration
- You must be willing to be included in a long-term registry (information collection)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This registry collects health and family information about people with Rett syndrome (or specific changes in the MECP2 gene). It helps researchers understand the condition better and plan future studies. Participation may include sharing information for living individuals or those who have passed away.
This trial tests a gene-editing approach for Rett syndrome in children who have a confirmed MECP2 gene mutation. It may help by targeting specific “hotspot” genetic changes that cause the condition.
This study measures brain and nerve activity (brain signals) to find patterns that match Rett syndrome. It may help researchers better track Rett changes over time and develop more precise ways to measure response in future treatments.
This study tests an investigational drug called NTI164 in girls and young women with Rett syndrome. It looks at how safe the drug is and whether it helps with symptoms. The study lasts for a period of time, and participants will be monitored closely.
This study measures brain waves and hearing in people with Rett syndrome to better understand how the condition affects the brain's ability to process sound. The information may help develop better treatments and support.
This trial tests an oral medication called NA-921 in females with Rett syndrome to see if it works better than a placebo. It may be an option for those who have a confirmed MECP2 gene mutation and stable seizure patterns.
Hear when a new Rett Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.